||Blobel CP. ADAMS: key components in EGFR signalling and development. Nat Rev Cancer, 6:32-43, 2005.
Arribas J, Bech-Serra JJ, Santiago-Josefat B ADAMs, cell migration and cancer. Cancer Metastasis Rev 25:57–68, 2006.
Ohtsu H, Dempsey PJ, Eguchi S ADAMs as mediators of EGF receptor transactivation by G-protein-coupled receptors. Am J Physiol Cell Physiol 291:C1–10, 2006
Mochizuki A, Okada Y ADAMs in cancer cell proliferation and progression. Cancer Sci 98:621-628, 2007.
Murphy G The ADAMs: signalling scissors in the tumor microenvironment. Nature Reviews Cancer, 8:929-941, 2008
Edwards DR, Handsley MM, Pennington CJ The ADAM metalloproteinases. Mol Aspects Med 29:258–289, 2008.
Duffy MJ, McKiernan E, O’Donovan N, McGowan P. Role of ADAMs in Cancer Formation and Progression. Clin Cancer Res 15:1140-1144, 2009.
McGowan PM, McKiernan E, Bolster F, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19:1075-1081, 2008.
Minn AJ, Kang Y, Serganova I,Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.J Clin Invest, 115, 44-55, 2005.
Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22:1114–1124, 2003.
Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNF α) shedding and of the function of the TNF α ectodomain in ensuring selective stimulated shedding by the TNF α convertase (TACE/ADAM17). J Biol Chem 41:42898-42906, 2004.
Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinases inhibitors in cancer treatment. Oncogene 19:6642–6650, 2000.
Zhou BB, Petyon M, He B, et al. Targeting ADAM-mediated ligand cleavage toinhibit HER2 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39–50, 2006.
Liu X, Fridman JS, Wang Q et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 5:648–656, 2006.
Fridman JS, Caulder E, Hansbury M. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13:1892–1902, 2007.
De Kok JB, Roelofs RW, Giesendorf BA et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85:154-159, 2005.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402-408, 2000.
Iba K, Albrechtsen R, Gilpin B, Fröhlich C, et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 149:1143–56, 2000.
Atfi A, Dumont E, Colland F, et al. The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J Cell Biol 178:201–208, 2007.
Dyczynska E, Syta E, Sun D, Zolkiewska A Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 122:2634-2640, 2008.
Le Pabic H, Bonnier D, Wewer UM, et al. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37:1056–1066, 2003.
Pories S, Zurakowski D, Roy R, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev, 17:1034-1042, 2008.
Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM12, a disintegrin and metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 275:18 574–18 580, 2000.
Laigaard J, Sørensen T, Fröhlich C, et al. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 23:1086–1091, 2003.
Roy R, Wewer MU, Zurakowski D, Pories ES, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 49:51323-51330, 2004.
O’Shea C, McKie N, Buggy Y, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105:754-761, 2003.
Lendeckel U, Kohl J, Arndt M, et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131:41-48, 2005.
Kuefer R, Day KC, Kleer CG, et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseases. Neoplasia 8:319–329, 2006.
Fröhlich C, Albrechtsen R, Dyrskjot L, et al. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 12:7359-7368, 2006.
Kodama T, Ikeda E, Okada A, et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 165:1743–1753, 2004.